Table 7. Health-related quality of life at baseline and at week 12.
HRQoL questionaire and scale | Week 0 | Week 12 | P | |||||
---|---|---|---|---|---|---|---|---|
Median | Q1 | Q3 | Median | Q1 | Q3 | |||
QLQ-C30 | ||||||||
Global health scale | ||||||||
Global health | 83 | 73 | 100 | 83 | 67 | 92 | 0.12 | |
Functional scales | ||||||||
Physical | 93 | 80 | 100 | 83 | 73 | 93 | 0.006 | |
Role | 100 | 83 | 100 | 92 | 67 | 100 | 0.15 | |
Emotional | 100 | 92 | 100 | 100 | 83 | 100 | 0.09 | |
Cognitive | 100 | 96 | 100 | 100 | 83 | 100 | 0.41 | |
Social | 100 | 100 | 100 | 100 | 100 | 100 | 0.34 | |
Symptom scales | ||||||||
Fatigue | 11 | 0 | 22 | 11 | 0 | 25 | 0.80 | |
Nausea/vomiting | 0 | 0 | 0 | 0 | 0 | 0 | 0.17 | |
Pain | 0 | 0 | 33 | 0 | 0 | 21 | 0.67 | |
Dyspnea | 0 | 0 | 33 | 0 | 0 | 0 | 0.76 | |
Sleep disturbance | 0 | 0 | 8 | 0 | 0 | 8 | 0.78 | |
Appetite loss | 0 | 0 | 0 | 0 | 0 | 0 | 0.07 | |
Constipation | 0 | 0 | 0 | 0 | 0 | 0 | 0.71 | |
Diarrhea | 0 | 0 | 0 | 0 | 0 | 0 | NA | |
Financial impact | 0 | 0 | 0 | 0 | 0 | 0 | NA | |
QLQ-PR25 | ||||||||
Functional scales | ||||||||
Sexual activity | 0 | 0 | 17 | 0 | 0 | 0 | 0.50 | |
Sexual functioning | Not reported, n=3 | Not reported, n=2 | NA | |||||
Symptom scales | ||||||||
Urinary symptoms | 19 | 13 | 34 | 19 | 13 | 39 | 0.41 | |
Bowel symptoms | 0 | 0 | 17 | 0 | 0 | 8 | 0.28 | |
Hormonal treatment-related symptoms | 17 | 11 | 28 | 17 | 11 | 22 | 0.29 | |
Incontinence aid (n=3) | 17 | 8 | 25 | 17 | 8 | 25 | NA |
The P values were calculated using the Wilcoxon signed-rank test. QLQ-C30, quality-of-life core 30; QLQ-PR25, quality of life questionnaire-Prostate Module 25; NA, not available.